Our Mission, Visions and Values

Mission
　Realization of a society beyond Dementia.


Vision
　We make a society where dementia is treatable and can old age people enjoy the life.
　We make a society where people use a diagnostic kit for dementia to select their social activities.


Value
・We socially implement research results on the mechanism of memory.
・We develop a simple blood diagnostic method that can evaluate cognitive symptoms.
・We treat dementia by developing drugs that prevent drebrin depletion and increase synaptic resilience.



Public support


1.Our company has been adopted as a research and development environment improvement support project in Tokyo.


2.Our company has been selected for the acceleration program of the Tokyo Metropolitan Restart Entrepreneur Support Project (TOKYO Re: STARTER).






 

CEO Tomoaki Shirao


After graduating from Gunma University School of Medicine, Dr. Shirao (MD) obtained a PhD degree in 1984 for the discovery of the actin-binding protein drebrin.

After working as an assistant professor at Gunma University School of Medicine, a researcher at Cornell University School of Medicine, an assistant professor at the National Institute of Physiology (NIPS), and an associate professor at Keio University, he became a full professor at Gunma University in 1993.

He has served as Vice President of Gunma University, Director of Heavy Ion Medical Promotion Organization, President of International Society, President of NPO Bioforum, Member of Science Council of Japan, etc., and became COEr of AlzMed,Inc. from 2020.

He is still one of the world leaders in the study of molecular mechanisms of memory.



【Link】

NPO Bioforum
https://www.bioforum.or.jp/greeting/


International Society of Radiation Neurobiology
http://isrnb.org/


Gunma University Graduate School of Medicine Department of Neurobiology and Behavior
http://neuro.dept.med.gunma-u.ac.jp/


Drebrin
http://neuro.dept.med.gunma-u.ac.jp/?page_id=92


Speciall Lecutre：Fourty year's research of Drebrin and its future. (YouTube)
https://www.youtube.com/watch?v=9vgkBT0Zynk

 

 

 

Company Profile
  • AlzMed, Inc. was established in 2019.
    We aim to implement the research results of the memory control function of the protein molecule "Drebrin" discovered by Tomoaki Shirao (President, Special Professor of Gunma University) in order to overcome Alzheimer's disease.

    For the first year after its establishment, we mainly worked to support the patenting of Drebrin research results.

    After Shirao became the representative director in 2020, he has been engaged in full-scale research and development activities in the diagnostic and drug discovery businesses at the Entrepreneur Lab, Division of University Corporate Relations, The University of Tokyo.

  • Company name
    　　 AlzMed, Inc.

  • President
    　　Tomoaki Shirao

  • Address
    　　Zip code : 113-8485
    　　Hongo 7-3-1, Bunkyo-ku, Tokyo Japan,Entrepreneurs laboratory UT South building
    　　+81-(0)-80-8087-9411
    　　(9:00～17:00)
  • Establishment
    　　February 27, 2019